Dow Jones

40 003,59

0,34%

DAX

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

S'inscrire

Accueil
Investir
Actions
Royaume-Uni
LSE
Moberg Pharma Ab (publ) (0P48)
Moberg Pharma Ab (publ) (0P48) Actualités

0P48

Moberg Pharma Ab (publ) (0P48)

Moberg Pharma Ab (publ)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:LSE:0P48

1 2 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
07/02/2024	08h12	UK Regulatory	MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication	LSE:0P48	Moberg Pharma Ab (publ)
28/06/2023	11h23	PR Newswire (US)	MOB-015 is recommended for approval in EU: Moberg Pharma	LSE:0P48	Moberg Pharma Ab (publ)
28/03/2022	08h10	PR Newswire (US)	European marketing authorization application for MOB-015 submitted	LSE:0P48	Moberg Pharma Ab (publ)
23/12/2021	08h12	PR Newswire (US)	The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application	LSE:0P48	Moberg Pharma Ab (publ)
22/09/2021	08h22	PR Newswire (US)	Moberg Pharma receives approval from the EMA's Paediatric Committee	LSE:0P48	Moberg Pharma Ab (publ)
09/02/2021	08h13	PR Newswire (US)	Moberg Pharmas Year-end report 2020	LSE:0P48	Moberg Pharma Ab (publ)
29/01/2021	13h23	PR Newswire (US)	Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record...	LSE:0P48	Moberg Pharma Ab (publ)
29/01/2021	08h37	PR Newswire (US)	New number of shares and votes in Moberg Pharma AB (publ)	LSE:0P48	Moberg Pharma Ab (publ)
07/01/2021	08h08	PR Newswire (US)	OncoZenge announces issue of European Patent related to BupiZenge®	LSE:0P48	Moberg Pharma Ab (publ)
11/12/2020	08h07	PR Newswire (US)	OncoZenge raises MSEK 10 ahead of spin-off and separate listing	LSE:0P48	Moberg Pharma Ab (publ)
30/11/2020	14h33	PR Newswire (US)	Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in Onco...	LSE:0P48	Moberg Pharma Ab (publ)
23/11/2020	08h41	PR Newswire (US)	Invitation to market update in Moberg Pharma on November 25th	LSE:0P48	Moberg Pharma Ab (publ)
16/11/2020	15h16	PR Newswire (US)	OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing	LSE:0P48	Moberg Pharma Ab (publ)
10/11/2020	09h02	PR Newswire (US)	Extended fiscal year July 2019 - December 2020 Interim report July - September 2020	LSE:0P48	Moberg Pharma Ab (publ)
06/11/2020	08h26	PR Newswire (US)	Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million	LSE:0P48	Moberg Pharma Ab (publ)
06/11/2020	08h25	PR Newswire (US)	Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI)	LSE:0P48	Moberg Pharma Ab (publ)
14/10/2020	08h27	PR Newswire (US)	Moberg Pharma intends to submit a registration application in Europe in 2021	LSE:0P48	Moberg Pharma Ab (publ)
11/08/2020	08h16	PR Newswire (US)	Moberg Pharma: Interim report April - June 2020	LSE:0P48	Moberg Pharma Ab (publ)
30/07/2020	08h27	PR Newswire (US)	Appointment of Chief Medical Officer at Moberg Pharma	LSE:0P48	Moberg Pharma Ab (publ)
30/06/2020	08h28	PR Newswire (US)	New number of Shares and Votes in Moberg Pharma AB (publ)	LSE:0P48	Moberg Pharma Ab (publ)
25/06/2020	08h26	PR Newswire (US)	Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study	LSE:0P48	Moberg Pharma Ab (publ)
29/05/2020	08h13	PR Newswire (US)	New Number of Shares and Votes in Moberg Pharma AB (publ)	LSE:0P48	Moberg Pharma Ab (publ)
12/05/2020	08h24	PR Newswire (US)	Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020	LSE:0P48	Moberg Pharma Ab (publ)
05/05/2020	08h14	PR Newswire (US)	Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference	LSE:0P48	Moberg Pharma Ab (publ)
27/03/2020	09h20	PR Newswire (US)	Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)	LSE:0P48	Moberg Pharma Ab (publ)
23/03/2020	21h17	PR Newswire (US)	Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015	LSE:0P48	Moberg Pharma Ab (publ)
11/02/2020	08h18	PR Newswire (US)	Moberg Pharma AB Interim Report October - December 2019	LSE:0P48	Moberg Pharma Ab (publ)
04/02/2020	08h13	PR Newswire (US)	Moberg Pharma's Interim Report to be Published on February 11 - Invitation to Teleconference	LSE:0P48	Moberg Pharma Ab (publ)
22/01/2020	08h21	PR Newswire (US)	Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015	LSE:0P48	Moberg Pharma Ab (publ)
12/12/2019	08h10	PR Newswire (US)	Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015	LSE:0P48	Moberg Pharma Ab (publ)